Acquisition Pending
Eli Lilly and Company acquisition of LimmaTech Biologics AG
US$780m consideration
Announced May 2026
Advisers
LimmaTech Biologics AG
Target
Eli Lilly and Company
Acquirer
- Target
- LimmaTech Biologics AG
- Acquirer
- Eli Lilly and Company
- Target based in
- Switzerland
- Buyer based in
- United States
- Sector
- Biotech
In the league tables
Similar deals
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Ligand Pharmaceuticals acquisition of XOMA Royalty Apr 2026 · US$739m · Specialty finance and leasing
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- Otsuka acquisition of Transcend Therapeutics Mar 2026 · US$700m · Biotech
Sources
- May 2026 Kirkland Advises Eli Lilly on Acquisition of LimmaTech Biologics kirkland.com
- 27 May 2026 Goodwin Advises LimmaTech Biologics on $780 Million Acquisition by Lilly goodwinlaw.com

